A Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women With Newly Diagnosed Breast Cancer and Germline BrCa Mutations
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 30 Aug 2021 Biomarkers information updated
- 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Aug 2012 New trial record